Intra Cellular Therapies reported $127.5M in Operating Expenses for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Expenses Change
Acadia Pharmaceuticals ACAD:US USD 161.58M 6.63M
ALKERMES ALKS:US USD 313M 2.32M
Aptinyx Inc APTX:US USD 14.66M 2.45M
Biocryst Pharmaceuticals BCRX:US USD 93.27M 6.98M
Biogen BIIB:US USD 1.19B 1.45B
Bristol Myers Squibb BMY:US USD 8.75B 552M
Cytokinetics CYTK:US USD 133.2M 33.36M
Esperion Therapeutics ESPR:US USD 60.6M 10.61M
Gilead Sciences GILD:US USD 4.2B 26M
Halozyme Therapeutics HALO:US USD 128.4M 10.09M
Intra Cellular Therapies ITCI:US USD 127.5M 16M
JAZZ PHA JAZZ:US USD 915.89M 68.56M
Johnson & Johnson JNJ:US USD 19.51B 1.54B
Marinus Pharmaceuticals MRNS:US USD 32.44M 6.12M
Minerva Neurosciences NERV:US USD 5.21M 1.76M
Nektar Therapeutics NKTR:US USD 77.93M 96.49M
Neurocrine Biosciences NBIX:US USD 300.1M 93.4M
Novartis NVS:US USD 10.67B 183M
Prothena PRTA:US USD 51.85M 7.33M
Supernus Pharmaceuticals SUPN:US USD 178.88M 20.17M
United Therapeutics UTHR:US USD 201.7M 63.4M
Vanda Pharmaceuticals VNDA:US USD 61.41M 481K